Amgen Inc. Todos os direitos reservados

What Amgen Inc. Todos os direitos reservados does

Amgen Inc. is a global biotechnology company founded in 1980 in Thousand Oaks, California, that develops, manufactures, and delivers biological medicines and biosimilars for serious diseases. Its portfolio spans seven therapeutic areas — oncology, hematology, bone health, inflammation, cardiovascular disease, neurology, and nephrology — with the Portuguese affiliate alone marketing 19 prescription medicines, including branded biologics such as BLINCYTO (acute lymphoblastic leukemia), REPATHA (hypercholesterolemia), PROLIA/XGEVA (bone health), LUMYKRAS (KRAS G12C-mutated lung cancer), and KYPROLIS (multiple myeloma), alongside a growing biosimilar line (AMGEVITA, KANJINTI, MVASI, WEZENLA). The company's underlying technology stack combines proprietary biological platforms — most notably a Proximity Platform for multiespecific drug development and a vertically integrated end-to-end biological manufacturing network — with AI/ML-driven Generative Biology for protein-structure prediction and discovery acceleration, augmented by the wholly-owned deCODE Genetics subsidiary, which supplies large-scale human genomic and multi-omic data for target identification and patient stratification.

Amgen's business model is the sale of prescription-only biological medicines through a sales-led go-to-market, organized by dedicated business units per therapeutic area (e.g., Onco-Hematology and Cardio-Renal in Portugal) and supported by medical representatives, medical information services, and pharmacovigilance functions. Revenue streams comprise global pharmaceutical product sales across 100+ countries plus biosimilar commercialization, with pricing determined through national reimbursement and payer negotiation (not publicly disclosed on the Portuguese site). Distribution flows through pharmaceutical wholesalers, hospital and retail pharmacies, and direct order handling in each market. The Portugal operation, established in 1993, runs both a commercial pharmaceutical affiliate (Amgen Biofarmacêutica, Lda) and the Amgen Capability Center Portugal — Amgen's first global capability center outside the United States, opened in 2021 and housing Data & Analytics, Digital Technology & Innovation, Cybersecurity, Regulatory, Finance, and Contracts & Pricing functions. Globally the company employs approximately 31,500 people, of whom roughly 400 are based in Portugal, and reaches millions of patients annually.

Name

Amgen Inc. Todos os direitos reservados

Legal name

Amgen - Biofarmacêutica, Lda

Website

https://amgen.pt

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Amgen Inc. is a global biotechnology company that develops, manufactures, and delivers biological medicines and biosimilars for serious diseases. It serves millions of patients across 100+ countries with a portfolio spanning oncology, hematology, bone health, inflammation, cardiovascular, neurology, and nephrology.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Oncology Biosimilars (HLAAAHAG)

Keywords

• Biological medicines
• Biosimilar pharmaceuticals
• Biopharmaceutical manufacturing
• Oncology drug development
• Prescription therapeutics

Headquarters

HQ city

Thousand Oaks

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Amgen generates revenue primarily from the global sale of prescription-only biological medicines. The company markets a portfolio of innovative medicines and biosimilars across therapeutic areas including oncology, hematology, bone health, inflammation, cardiovascular disease, neurology, and nephrology. Presence in more than 100 countries.
2. Biosimilar Commercialization: Amgen develops and commercializes biosimilar medicines, leveraging its 40+ years of biotechnology experience. Biosimilars are biological medicines highly similar to approved reference products with no clinically significant differences in quality, safety, or efficacy.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Amgen develops, manufactures, and commercializes prescription-only biological medicines and biosimilars for serious diseases. Its portfolio spans oncology, hematology, bone health, inflammation, cardiovascular disease, neurology, and nephrology, with 19 medicines listed on the Portuguese website.

Product overview

Amgen is a global biotechnology company with a portfolio of 19 prescription medications available in Portugal, including innovative biologics and biosimilars. The portfolio spans therapeutic areas including oncology and hematology, bone diseases, inflammation, cardiovascular diseases, and nephrology. The company offers branded prescription medications (such as BLINCYTO for leukemia, REPATHA for cholesterol, PROLIA/XGEVA for bone health) alongside a biosimilar product line (including AMGEVITA, KANJINTI, MVASI, WEZENLA) that provides more affordable treatment options. The company's R&D pipeline focuses on areas of unmet medical need, with research into multispecific medicines and next-generation biologics.

Differentiator

Problem solved

Functional benefit

Products and services

• ARANESP® (darbepoetina alfa) Prescription medication listed in Amgen's Portuguese portfolio for the treatment of anemia.
• AMGEVITA® (adalimumab) Biosimilar prescription medication for inflammatory diseases.
• BEKEMV® (eculizumab) Prescription medication listed in Amgen's Portuguese portfolio.
• BLINCYTO® (blinatumomab) Prescription medication for hematological malignancies, specifically acute lymphoblastic leukemia.
• IMLYGIC® (talimogene laherparepvec) Prescription medication for melanoma and described as an oncolytic immunotherapy.
• KANJINTI® (trastuzumab) Biosimilar prescription medication for HER2-positive breast cancer.
• KYPROLIS® (carfilzomib) Prescription medication for multiple myeloma.
• LUMYKRAS® (sotorasib) Prescription medication for KRAS G12C-mutated lung cancer.
• MIMPARA® (cinacalcet) Prescription medication for hypercalcemia and secondary hyperparathyroidism.
• MVASI® (bevacizumab) Biosimilar prescription medication for various cancers, including colorectal, lung, and breast cancer.
• NEULASTA® (pegfilgrastim) Prescription medication for neutropenia that reduces infection risk during chemotherapy.
• NPLATE® (romiplostim) Prescription medication for immune thrombocytopenia.
• OTEZLA® (apremilast) Prescription medication for psoriasis and psoriatic arthritis.
• PARSABIV® (etelcalcetido) Prescription medication for secondary hyperparathyroidism in chronic kidney disease.
• PROLIA® (denosumab) Prescription medication for osteoporosis and bone loss that reduces fracture risk.
• REPATHA® (evolocumab) Prescription medication for hypercholesterolemia and a PCSK9 inhibitor that lowers LDL cholesterol.
• VECTIBIX® (panitumumab) Prescription medication for metastatic colorectal cancer.
• WEZENLA® (ustecinumab) Biosimilar prescription medication for psoriasis and inflammatory bowel disease.
• XGEVA® (denosumab) Prescription medication for bone metastases and giant cell tumor of bone.

Quantifiable outcome

• Reaching millions of patients in more than 100 countries with life-changing medicines
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Arthritis FoundationminorOthersAmgen provides educational resources and information about biosimilars through the Arthritis Foundation as part of its patient education support, helping patients with arthritis understand biosimilar alternatives for biologic treatments.
• Crohn's & Colitis FoundationminorOthersAmgen supports patient education through the Crohn's & Colitis Foundation, providing resources about inflammatory bowel disease and biosimilar treatment options for patients with Crohn's disease and ulcerative colitis.
• Global Healthy Living Foundation (GHLF)minorOthersAmgen supports patient education resources through GHLF, including the Creaky Joints platform which provides information about biosimilars and answers common patient questions about biologic treatments.
• National Psoriasis FoundationminorOthersAmgen provides educational resources about biosimilars through the National Psoriasis Foundation to help patients with psoriasis understand their treatment options including biologic therapies.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreOthersAmgen complies with EFPIA transparency codes, disclosing transfers of value to healthcare professionals and healthcare organizations, and participates in EFPIA transparency reporting frameworks including the HCP/HCO Disclosure Code.
• INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.)coreOthersAmgen operates under INFARMED regulations for transparency and disclosure of pharmaceutical industry activities in Portugal, complying with Article 159 of Decree-Law 176/2006 and EFPIA codes for transparency reporting.
• Amgen FoundationcoreStrategic or Co-development PartnerThe Amgen Foundation works to expand access to engaging and inspiring science education programs, providing future generations with essential skills to thrive in an increasingly complex world. It supports science education initiatives globally.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Gilead Sciences: Independent large-cap biotechnology company with a comparable focus on specialty therapeutics including oncology, inflammation, and HIV. Like Amgen, Gilead develops and commercializes innovative biologics globally and operates a vertically integrated biologics manufacturing footprint.
• Regeneron Pharmaceuticals: Independent biotechnology company developing antibody-based biologics across ophthalmology, inflammation, oncology, and rare diseases. Comparable to Amgen in its proprietary technology platforms (VelocImmune), biologics manufacturing scale, and pipeline-driven growth model.
• Vertex Pharmaceuticals: Independent large-cap biotech with a specialty-care focus and pipeline depth in serious diseases. Comparable to Amgen in its therapeutic-area concentration, biologics/small-molecule portfolio, and reliance on a few high-value franchises.
• Biogen: Independent biotechnology company with a specialty focus on neurology and rare diseases. Comparable to Amgen as a focused biotech with biologics manufacturing expertise and pipeline-driven growth, although narrower in therapeutic-area breadth.

Broad incumbents

• Bristol-Myers Squibb: Global biopharmaceutical incumbent with major oncology, hematology, cardiovascular, and immunology franchises. Directly competes with Amgen across several of its largest therapeutic areas and operates a broader portfolio at greater scale.
• Roche: Global biopharmaceutical incumbent with leading oncology and biologics franchises through Genentech. Comparable to Amgen in biologics focus and oncology competition (BLINCYTO vs. Roche hematology assets), but operates at substantially larger scale with a broader portfolio.
• Pfizer: Global biopharmaceutical incumbent with major oncology, inflammation, cardiovascular, and biosimilars businesses. Comparable to Amgen across multiple therapeutic areas and a direct competitor in the biosimilars space.
• Merck & Co. Global biopharmaceutical incumbent with a leading oncology franchise (Keytruda). Comparable to Amgen as a competitor in oncology and as a diversified biologics/small-molecule manufacturer with global commercial reach.
• Johnson & Johnson (Innovative Medicine): Global healthcare incumbent with major immunology, oncology, hematology, and bone-health franchises (including biosimilars). Comparable to Amgen across multiple therapeutic areas and a direct competitor in immunology, oncology, and biosimilars.
• Eli Lilly: Global biopharmaceutical incumbent with diversified oncology, immunology, cardiometabolic, and neuroscience franchises. Comparable to Amgen as a competitor in cardiometabolic disease (REPATHA vs. Lilly lipid franchise) and immunology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amgen

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amgen Inc. Todos os direitos reservados